4d
Cyclingnews on MSNSean Kelly's Classics Column: Tadej Pogačar would be crazy to ride Paris-RoubaixEven after his Strade Bianche victory, it would be crazy for Tadej Pogačar to ride Paris-Roubaix this year.
SIENA, Italy (AP) — Bruised and bloodied, Tadej Pogacar still managed to solo to victory on Saturday. The defending champion recovered from a heavy crash to become only the second cyclist to win ...
Slovenia's Tadej Pogacar won the Strade Bianche on Saturday for the third time in his career, after recovering from a fall 50km from the finish. Pogacar topped the podium by 1min 24sec ahead of ...
Pogacar of Team UAE topped the podium by 1min 24sec ahead of Briton Tom Pidcock, with Belgium's Tim Wellens a further 48sec adrift. After victory in the Tuscan one-day race in 2022 and 2024, 26 ...
FLORENCE – Slovenia’s Tadej Pogacar won the Strade Bianche on March 8 for the third time in his career, after recovering from a fall 50km from the finish. The Team UAE rider topped the podium ...
A true warrior and a real winner, Tadej Pogacar wins the Strade Bianche three times—and the first to go back-to-back—witb scrapes on his left leg and arm, with his skinsuit torn up.
After the adrenaline in his body had subsided, Tadej Pogacar gradually felt the pain. Nevertheless, the joy of his impressive coup at the Strade Bianche gravel race prevailed. "It's not the nicest ...
LeBron James isn’t the only one who seems to have an issue with how Stephen A. Smith has been talking about Bronny James. In a long diatribe on his show, “The Stephen A. Smith Show,” the ...
The possibility of Tadej Pogačar riding this year's Paris-Roubaix has fallen after his crash at Strade Bianche, with UAE Team Emirates-XRG manager Mauro Gianetti preferring to avoid any risks ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results